KRW 18200.0
(0.94%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | 1.37 Billion KRW | 18.7% |
2022 | 1.15 Billion KRW | 5.98% |
2021 | 1.09 Billion KRW | 6.24% |
2020 | 1.02 Billion KRW | 26.19% |
2019 | 815.01 Million KRW | 41.99% |
2018 | 573.98 Million KRW | -52.37% |
2017 | 1.2 Billion KRW | 72.09% |
2016 | 700.26 Million KRW | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q2 | 1.63 Billion KRW | 11.56% |
2024 Q1 | 1.46 Billion KRW | 6.47% |
2023 FY | 1.37 Billion KRW | 18.7% |
2023 Q2 | 1.35 Billion KRW | -6.29% |
2023 Q3 | 1.8 Billion KRW | 33.51% |
2023 Q4 | 1.37 Billion KRW | -23.79% |
2023 Q1 | 1.44 Billion KRW | 24.49% |
2022 Q2 | 1.15 Billion KRW | -5.95% |
2022 FY | 1.15 Billion KRW | 5.98% |
2022 Q4 | 1.15 Billion KRW | 15.7% |
2022 Q3 | 1 Billion KRW | -13.54% |
2022 Q1 | 1.23 Billion KRW | 12.65% |
2021 Q3 | 1.14 Billion KRW | 0.0% |
2021 FY | 1.09 Billion KRW | 6.24% |
2021 Q4 | 1.09 Billion KRW | -4.45% |
2020 FY | 1.02 Billion KRW | 26.19% |
2019 FY | 815.01 Million KRW | 41.99% |
2018 FY | 573.98 Million KRW | -52.37% |
2017 FY | 1.2 Billion KRW | 72.09% |
2016 FY | 700.26 Million KRW | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
HLB Pharmaceutical Co., Ltd | 20.85 Billion KRW | 93.41% |
CMG Pharmaceutical Co., Ltd. | 15.87 Billion KRW | 91.342% |
Celltrion Pharm, Inc. | 100.42 Billion KRW | 98.631% |
Huons Global Co., Ltd. | 121.81 Billion KRW | 98.872% |
DongKook Pharmaceutical Co., Ltd. | 138.34 Billion KRW | 99.006% |
Enzychem Lifesciences Corporation | 14.94 Billion KRW | 90.803% |
Humedix Co., Ltd. | 28.62 Billion KRW | 95.198% |
Boditech Med Inc. | 31.6 Billion KRW | 95.651% |
EuBiologics Co., Ltd. | 13.34 Billion KRW | 89.698% |
Huons Co., Ltd. | 76.59 Billion KRW | 98.206% |
BNC Korea Co., Ltd. | 11.39 Billion KRW | 87.936% |
AptaBio Therapeutics Inc. | - KRW | -Infinity% |